{
    "clinical_study": {
        "@rank": "67146", 
        "arm_group": [
            {
                "arm_group_label": "VINCI Plus", 
                "arm_group_type": "Experimental", 
                "description": "One side has been treated with VINCI Plus"
            }, 
            {
                "arm_group_label": "Restylane-L", 
                "arm_group_type": "Active Comparator", 
                "description": "One side has been treated with Restylane-L"
            }
        ], 
        "brief_summary": {
            "textblock": "This clinical trial is intended to evaluate the efficacy and safety of injection with VINCI\n      Plus as compared to Restylane-L\u00ae in correction of nasolabial fold."
        }, 
        "brief_title": "Efficacy and Safety of Injection With VINCI Plus Hyaluronic Acid Filler", 
        "condition": "Nasolabial Fold Improvement", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female between the ages of 30-65, at the point of screening, wrinkles on both\n             sides of treatment area (nasolabial fold) are in the 3rd or 4th level on the\n             WSRS(Wrinkle Severity Rating Score)\n\n          -  Surrounding soft tissue of wrinkles on both sides of nose and lips are sagging\n\n          -  Wrinkles of both sides of nose and lips are visually symmetric\n\n          -  Agrees to stop all other treatment of facial wrinkle improvement including\n             dermatology treatment during clinical trial\n\n          -  Able to understand and follow instructions and participate the entire period of the\n             clinical trial\n\n          -  Subject voluntarily agrees to participate in clinical trial and gives informed\n             written consent\n\n        Exclusion Criteria:\n\n          -  At the point of screening, intradermal test results show skin irritation to medical\n             devices of clinical trial\n\n          -  Within 2 weeks before the date of screening, subject has taken antithrombotic (with\n             the exception of low dose aspirin 100mg, up to 300mg/day) or non-steroidal\n             anti-inflammatory medication\n\n          -  Case where subject has abnormal liver function or blood coagulation, has to take\n             antithrombotic medication (with the exception of low dose aspirin 100mg, up to\n             300mg/day) during clinical trial\n\n          -  Subject has used facial topical liniment (steroids, retinoids: excluding only\n             medicines and cosmetics) within 4 weeks before date of screening or plans to continue\n             using facial topical liniment during clinical trial\n\n          -  Within 6 months before date of screening, subject has received anti-wrinkle or acne\n             treatment\n\n          -  Within 6 months before date of screening, subject has received facial\n             microdermabrasion treatment, skin regeneration/rejuvenation treatment, plastic\n             surgery, or cosmetic surgery (including Botox injections)\n\n          -  Within 1 year before date of screening, subject has received CaHA (Calcium\n             Hydroxyapatite) treatment on clinical trial medical device treatment area\n\n          -  Subject has cured facial gel (Softform) or silicone implants inserted as permanent\n             facial expansion\n\n          -  Within 1 year before, subject had an illness that caused scarring or has scars on\n             clinical trial medical device treatment area\n\n          -  Subject has facial skin disease or skin wound infection that affects the clinical\n             trial\n\n          -  Weak immune system or suspect that the immune system is weak\n\n          -  History of anaphylaxis or severe allergic complexity\n\n          -  History of hypertrophic scar or keloid\n\n          -  In the past, if there were adverse effects from EMLA Cream (if EMLA Cream was not\n             used, the exclusion criteria for subjects applicable)\n\n          -  History of hypersensitivity to Lidocaine\n\n          -  Cardiovascular, digestive, respiratory, endocrine, central nervous system disorders\n             that seems clinically significant or had a mental illness that had a significant\n             impact on a previous clinical trial or currently has a mental illness\n\n          -  Within 30 days before screening, subject participated in other clinical trials\n\n          -  Female subjects of childbearing potential does not agree to a medically accepted\n             method of contraception for the period of the clinical trial Medically acceptable\n             methods of contraception: condoms; oral contraception continued for at least three\n             months; or if intrauterine is used, installed a contraceptive device\n\n          -  Pregnant women or nursing mothers\n\n          -  In addition to the above, the test director or person in charge medically judges\n             there are clinically significant findings that are improper for the clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "46", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01918839", 
            "org_study_id": "DMEDVINCI001", 
            "secondary_id": "DMEDVINCI001"
        }, 
        "intervention": [
            {
                "arm_group_label": "VINCI Plus", 
                "description": "VINCI Plus 1ml injected into wrinkle treatment area", 
                "intervention_name": "VINCI Plus", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Restylane-L", 
                "description": "Restylane-L injected into wrinkle treatment area", 
                "intervention_name": "Restylane-L", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Investigational Device (VINCI Plus)", 
            "Correction of nasolabial fold", 
            "Wrinkle improvement", 
            "Wrinkle correction"
        ], 
        "lastchanged_date": "January 17, 2014", 
        "location": [
            {
                "contact": {
                    "email": "lionheo@snu.ac.kr", 
                    "last_name": "Chanyeong Heo, Professor", 
                    "phone": "+82317877222"
                }, 
                "facility": {
                    "address": {
                        "city": "Seongnam", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do"
                    }, 
                    "name": "Seoul National University Hospital"
                }, 
                "investigator": {
                    "last_name": "Changsik Park", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "beomjoon74@gmail.com", 
                    "last_name": "Bumjoon Kim, Professor", 
                    "phone": "+8227489573"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Chung-Ang University Hospital"
                }, 
                "investigator": {
                    "last_name": "Inkwon Yeo", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Clinical Study to Evaluate the Efficacy and Safety of Injection With VINCI Plus as Compared to Restylane-L in Correction of Nasolabial Fold", 
        "overall_contact": {
            "email": "beomjoon74@gmail.com", 
            "last_name": "Bumjoon Kim, Professor", 
            "phone": "+8227489573"
        }, 
        "overall_contact_backup": {
            "email": "lionheo@snu.ac.kr", 
            "last_name": "chanyeong Heo, Professor", 
            "phone": "+82317877222"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "South Korea: Institutional Review Board", 
                "South Korea: Korea Food and Drug Administration (KFDA)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Wrinkle Severity Rating Scale (WSRS) evaluation at 12 weeks", 
            "measure": "Wrinkle Severity Rating Scale (WSRS) Evaluation", 
            "safety_issue": "No", 
            "time_frame": "At 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01918839"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Wrinkle Severity Rating Scale (WSRS) Evaluation at 2 weeks, and 6 weeks.", 
                "measure": "Wrinkle Severity Rating Scale (WSRS) Evaluation", 
                "safety_issue": "No", 
                "time_frame": "At 2 weeks, 6 weeks"
            }, 
            {
                "description": "Global Aesthetic Improvement Scale (GAIS) Evaluation at 2 weeks, 6 weeks and 12 weeks.", 
                "measure": "Global Aesthetic Improvement Scale (GAIS) Evaluation", 
                "safety_issue": "No", 
                "time_frame": "At 2 weeks, 6 weeks and 12 weeks"
            }, 
            {
                "description": "VAS pain assessment at each time point (at injection and 15, 30, 45, and 60 min after injection)", 
                "measure": "VAS pain assessment at each time point", 
                "safety_issue": "No", 
                "time_frame": "at injection and 15, 30, 45, and 60 min after injection"
            }
        ], 
        "source": "D.med", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Chung-Ang University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Seoul National University Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "D.med", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}